Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 reduced-toxicity myeloablative conditioning with fludarabine and intravenous busulfan in pediatric allo-HSCT
2011-004764-30Phase 2Completed
- Sponsor
- CHU de Nantes
- Start
- Oct 2011
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of fludarabine and busulfan in hematopoietic malignancies, sponsored by CHU de Nantes. Primary endpoint: Transplant-related mortality at 12 months. Started Oct 2011; status: completed.
02
Drugs
fludarabinebusulfan
03
Conditions
hematopoietic malignancies
Beyond the preview
Go deeper on 2011-004764-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-004764-30.